Capital Fund Management S.A. Bluebird Bio, Inc. Transaction History

Capital Fund Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $758,999 - $1.35 Million	-258,163 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.07 - $10.6 $638,786 - $1.66 Million	156,950 Added 155.07%	258,163 $1.25 Million
Q4 2021 Feb 10, 2022	BUY	$8.96 - $16.31 $809,831 - $1.47 Million	90,383 Added 834.56%	101,213 $1.01 Million
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $158,236 - $295,638	-14,078 Reduced 56.52%	10,830 $134,000
Q2 2021 Aug 12, 2021	BUY	$18.04 - $22.09 $303,108 - $371,156	16,802 Added 207.28%	24,908 $515,000
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $26,861 - $35,275	572 Added 7.59%	8,106 $711,000
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $1.05 Million - $1.66 Million	-17,801 Reduced 70.26%	7,534 $747,000
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $2.68 Million - $3.82 Million	25,335 New	25,335 $4.33 Million

20.2M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $310M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.